LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
SOUTH SAN FRANCISCO, Calif., March 01, 2016 -- Fluidigm Corporation (NASDAQ:FLDM) today announced that Chief Executive Officer and President Gajus Worthington will present and participate in a Q&A session at the Cowen and Company 36th Annual Health Care Conference in Boston on Tuesday, March 8, 2016, from 10:40 – 11:10 a.m. (EST).
Audio of Fluidigm’s presentation will be webcast at: http://wsw.com/webcast/cowen30/fldm.
The webcast will be archived for 90 days following the live presentation.
About Fluidigm
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for growth markets such as single-cell biology and production genomics. We sell to leading academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multi-parameter mass cytometry technology, and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs, while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account (@Fluidigm), Facebook page (https://www.facebook.com/Fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Fluidigm and the Fluidigm logo are trademarks or registered trademarks of Fluidigm Corporation.
Contact: Fluidigm Corporation Ana Petrovic Director, Investor Relations & Strategy 650.243.6628 (Office) [email protected]
